TABLE 2.
Clinical characteristics of patients from GSE106291 included in the validation study.
| High risk (n = 56) | Low risk (n = 67) | P | |
|---|---|---|---|
| Age | 0.908562 | ||
| ≥60 | 27 | 33 | |
| <60 | 29 | 34 | |
| Sex | 0.192443 | ||
| Male | 26 | 39 | |
| Female | 30 | 28 | |
| RUNX1_mutation | 0.642099 | ||
| Yes | 11 | 11 | |
| No | 45 | 56 | |
| RUNX1-RUNX1T1_fusion | 0.476547 | ||
| Yes | 1 | 4 | |
| No | 55 | 63 | |
| Treatment response | 0.641233 | ||
| resistant | 19 | 20 | |
| sensitive | 34 | 43 | |
| Life status | 0.115523 | ||
| Alive | 15 | 27 | |
| Dead | 41 | 40 |
Abbreviation: RUNX1, runt-related transcription factor 1; RUNX1T1, rUNX1 partner transcriptional co-repressor 1. Significant P value is in bold typeface.